Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) is a specialty pharmaceutical company focused on testosterone replacement therapy, best known for its oral product JATENZO. The company entered the public markets through a SPAC merger in 2021 and filed a Form S-1 registration statement on September 30, 2021, with accession number 0001213900-21-050782, covering resale shares tied to the de-SPAC transaction. Operating in the healthcare and specialty pharma sector, Clarus Therapeutics represents one of several biopharma names to access the public markets via the SPAC route during the 2021 peak of blank-check activity. Sign up on SpacDesk for the full filing history, deal timeline, and data on CRXT and hundreds of other SPAC transactions.